Compare GoPro Inc (GPRO) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GoPro Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? GoPro Inc trades at $1.1 (market cap $243.50M), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Maravai LifeSciences Holdings Inc. Class A Common Stock is far larger — about 4× GoPro Inc's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, GoPro Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GoPro Inc for 45 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| GPRO | MRVI | |
|---|---|---|
Market Cap | $243.50M | $972.90M |
Volume | 7,074,005 | 4,325,710 |
Sector | Technology | Health |
52-Week High | $2.31 | $9.00 |
52-Week Low | $0.58 | $2.83 |
Typical Hold Time | 45 Days | 0 Days |
Enterprise Value | $302.28M | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoPro trades at $1.16, down 2.52% today, as the stock consolidates after a volatile surge driven by merger news and influencer investment. The company faces fundamental challenges with negative profit margins and cash flow, though valuation ratios appear attractive with P/E of 4.56 and P/S of 0.34. Recent developments include a $285 million merger agreement with Starman Optical and YouTube creator Markiplier taking an 8.5% stake, driving significant price volatility.
The merger with Starman Optical offers strategic repositioning into AI data centers and defense markets, but shareholder lawsuits question the $1.14 per share valuation. While technical indicators show bullish momentum, fundamental weaknesses and competitive pressures from smartphones create significant investment risk. Analyst consensus remains cautious with only 21% buy ratings.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
